APLS Nasdaq· Apellis Pharmaceuticals Inc.
FundamentalsNews digest Peer analysis
APLS Nasdaq· Apellis Pharmaceuticals Inc.
Earnings report Q4 2023

Apellis Pharmaceuticals Reports Significant Increase in Revenue in Latest Quarter

Segments of revenue

In the latest quarter, Apellis Pharmaceuticals reported total revenue of $396.6 million. This consisted of $366.3 million in product revenue, net and $30.3 million in licensing and other revenue.


Apellis Pharmaceuticals experienced a substantial increase in revenue compared to the previous quarters. The product revenue, net increased from $65.1 million in the same quarter last year to $366.3 million in the latest quarter. This significant growth can be attributed to the successful launch and increased sales of their products. The management highlighted the strong demand for their pharmaceutical products and the positive market response as key factors contributing to the revenue growth.


Despite the impressive revenue growth, Apellis Pharmaceuticals still reported a net operating loss of $517.1 million in the latest quarter. This indicates that the company's operating expenses exceeded its revenue. The high operating expenses, particularly in research and development and general and administrative areas, continue to pose a challenge for the company. Additionally, the loss on conversion of debt and interest expenses further impacted the financial performance.


It is worth noting that Apellis Pharmaceuticals has been actively investing in research and development, which is reflected in the significant increase in expenses in this area. The company's commitment to innovation and development of new pharmaceutical products is evident in their financial statements.


Apellis Pharmaceuticals demonstrated a strong performance in terms of revenue growth in the latest quarter. The substantial increase in product revenue, net indicates the successful launch and increased sales of their pharmaceutical products. However, the company still faces challenges in managing its operating expenses, resulting in a net operating loss. The management's focus on research and development highlights their commitment to innovation and future growth. Overall, Apellis Pharmaceuticals' revenue growth is a positive indicator of their market position and potential for future success.

Source documents

Form 10-K  filed on Feb 27, 2024
26 pages scanned

Reference data

Company financials Q4 revenue 146M
Analyst estimates Q4 EPS missed by -26.31%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.